The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer

被引：0

作者：

Poma, A. ^{[1
]}

Pasquini, G. ^{[2
]}

Bruno, R. ^{[3
]}

Ali, G. ^{[3
]}

Proietti, A. ^{[3
]}

Pecora, I. ^{[2
]}

Petrini, L. ^{[2
]}

Vasile, E. ^{[2
]}

Chella, A. ^{[4
]}

Fontanini, G. ^{[1
]}

机构：

[1] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy

[2] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy

[3] Univ Hosp Pisa, Anat Pathol Unit, Pisa, Italy

[4] Azienda Osped Univ Pisana, Pneumo Oncol, Pisa, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

lung cancer; PD-L1; immunotherapy;

D O I：

10.1016/j.jtho.2019.08.969

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.04-66

引用

页码：S466 / S467

页数：2

共 50 条

[41] The role of PD-L1 in EGFR-mutant non-small cell lung cancer
Gao, Wentao
Wang, Lingling
Zhao, Yanyan
Zhu, Lucheng
DISCOVER ONCOLOGY, 2025, 16 (01)
[42] PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
Scheel, Andreas H.
Ansen, Sascha
Schultheis, Anne M.
Scheffler, Matthias
Fischer, Rieke N.
Michels, Sebastian
Hellmich, Martin
George, Julie
Zander, Thomas
Brockmann, Michael
Stoelben, Erich
Groen, Harry
Timens, Wim
Perner, Sven
von Bergwelt-Baildon, Michael
Buettner, Reinhard
Wolf, Juergen
ONCOIMMUNOLOGY, 2016, 5 (05):
[43] MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Kim, Eun Young
Kim, Arum
Kim, Se Kyu
Chang, Yoon Soo
LUNG CANCER, 2017, 110 : 63 - 67
[44] Landscape Heterogeneity of PD-L1 Expression and Immune Cells Predicts Prognosis of Metastatic Non-Small Cell Lung Cancer
Wu, J.
Sun, W.
Yang, X.
Wang, H.
Liu, X.
Chi, K.
Zhou, L.
Huang, X.
Zhao, S.
Ding, T.
Meng, B.
Lin, D.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S203 - S204
[45] Molecular Epidemiology of Programmed Cell Death 1-Ligand 1 (PD-L1) Protein Expression in Non-Small Cell Lung Cancer
Schabath, Matthew
Dalvi, Tapashi
Dai, Hongyue
Crim, Alan
Midha, Anita
Shire, Norah
Walker, Jill
Greenawalt, Danielle
Lawrence, David
Rigas, James
Brody, Robert
Potter, Danielle
Kumar, Naveen
Huntsman, Shane
Grays, Jhanelle
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S475 - S476
[46] The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer
Kim, Gun-Jik
Lee, Jae-Ho
Park, Won-Jin
Lee, Hye-Won
Hwang, Il-Seon
Lee, Deok Heon
ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2019, 49 (03) : 317 - 323
[47] PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
Jiang, Liyan
Su, Xinying
Zhang, Tianwei
Yin, Xiaolu
Zhang, Meizhuo
Fu, Haihua
Han, Hulin
Sun, Yun
Dong, Lili
Qian, Jialin
Xu, Yanhua
Fu, Xuan
Gavine, Paul R.
Zhou, Yanbin
Tian, Kun
Huang, Jiaqi
Shen, Dong
Jiang, Haiyi
Yao, Yihong
Han, Baohui
Gu, Yi
ONCOTARGET, 2017, 8 (16) : 26845 - 26857
[48] Investigation of response factors for monotherapy with immune checkpoint inhibitors in non-small cell lung cancer patients with PD-L1 expression <50%
Takahara, Yutaka
Abe, Ryudai
Sumito, Nagae
Tanaka, Takuya
Ishige, Yoko
Shionoya, Ikuyo
Yamamura, Kouichi
Nishiki, Kazuaki
Nojiri, Masafumi
Kato, Ryo
Shinomiya, Shohei
Oikawa, Taku
THORACIC CANCER, 2023, 14 (27) : 2754 - 2760
[49] PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer
Wang, Gang
Ionescu, Diana N.
Lee, Cheng-Han
Hiruki, Tadaaki
Myers, Renelle
Shaipanich, Tawimas
Lam, Stephen
Melosky, Barbara
Zhou, Chen
LUNG CANCER, 2019, 136 : 1 - 5
[50] Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Vecchiarelli, S.
D'Incecco, A.
Minuti, G.
Gallo, M.
De Luca, A.
Landi, L.
Bennati, C.
Spreafico, M.
D'Arcangelo, M.
Attilia, L.
Mazza, V.
Normanno, N.
Cappuzzo, F.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2389 - S2389

← 1 2 3 4 5 →